These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 24188025)

  • 1. Sunitinib malate in the treatment of urothelial cancer.
    Pons F; Bellmunt J
    Expert Opin Investig Drugs; 2014 Jan; 23(1):115-24. PubMed ID: 24188025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
    Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
    Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib malate for the treatment of renal cell carcinoma.
    Wood L
    Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
    Schneider BJ; Gadgeel SM; Ramnath N; Wozniak AJ; Dy GK; Daignault S; Kalemkerian GP
    J Thorac Oncol; 2011 Jun; 6(6):1117-20. PubMed ID: 21512407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM; Gebhard DF; Andresen CJ
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors.
    Bisht S; Feldmann G; Brossart P
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):777-88. PubMed ID: 23590356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.
    Mena AC; Pulido EG; Guillén-Ponce C
    Anticancer Drugs; 2010 Jan; 21 Suppl 1():S3-11. PubMed ID: 20110785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib: from rational design to clinical efficacy.
    Chow LQ; Eckhardt SG
    J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships between the effect of sunitinib and immature blood vessels in metastatic renal cell cancer.
    Kim BH; Sohn JC; Ha JY; Park CH; Choe MS; Jung HR; Kim CI
    Urol Int; 2015; 94(2):137-43. PubMed ID: 25138147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer.
    Rolfo C; Raez LE; Bronte G; Santos ES; Papadimitriou K; Buffoni L; van Meerbeeck JP; Russo A
    Expert Opin Investig Drugs; 2013 Aug; 22(8):1081-8. PubMed ID: 23790097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential of sunitinib as a therapy in ovarian cancer.
    Leone Roberti Maggiore U; Valenzano Menada M; Venturini PL; Ferrero S
    Expert Opin Investig Drugs; 2013 Dec; 22(12):1671-86. PubMed ID: 24070205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunitinib malate for the treatment of pancreas malignancies--where does it fit?
    Mankal P; O'Reilly E
    Expert Opin Pharmacother; 2013 Apr; 14(6):783-92. PubMed ID: 23458511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of sunitinib in patients with metastatic urothelial cancer.
    Gallagher DJ; Milowsky MI; Gerst SR; Ishill N; Riches J; Regazzi A; Boyle MG; Trout A; Flaherty AM; Bajorin DF
    J Clin Oncol; 2010 Mar; 28(8):1373-9. PubMed ID: 20142593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-angiogenic therapy: concept to clinic.
    Young RJ; Reed MW
    Microcirculation; 2012 Feb; 19(2):115-25. PubMed ID: 22078005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects.
    Silay MS; Miroglu C
    Med Hypotheses; 2007; 69(4):892-5. PubMed ID: 17368754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early development of sunitinib in hepatocellular carcinoma.
    Zhu AX; Raymond E
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):143-50. PubMed ID: 19105714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sunitinib for the treatment of thyroid cancer.
    Gómez-Sáez JM
    Expert Opin Investig Drugs; 2016 Nov; 25(11):1345-1352. PubMed ID: 27677828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland.
    Purmonen T; Martikainen JA; Soini EJ; Kataja V; Vuorinen RL; Kellokumpu-Lehtinen PL
    Clin Ther; 2008 Feb; 30(2):382-92. PubMed ID: 18343276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
    Saltz LB; Rosen LS; Marshall JL; Belt RJ; Hurwitz HI; Eckhardt SG; Bergsland EK; Haller DG; Lockhart AC; Rocha Lima CM; Huang X; DePrimo SE; Chow-Maneval E; Chao RC; Lenz HJ
    J Clin Oncol; 2007 Oct; 25(30):4793-9. PubMed ID: 17947727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
    Bridgeman VL; Vermeulen PB; Foo S; Bilecz A; Daley F; Kostaras E; Nathan MR; Wan E; Frentzas S; Schweiger T; Hegedus B; Hoetzenecker K; Renyi-Vamos F; Kuczynski EA; Vasudev NS; Larkin J; Gore M; Dvorak HF; Paku S; Kerbel RS; Dome B; Reynolds AR
    J Pathol; 2017 Feb; 241(3):362-374. PubMed ID: 27859259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.